Physician profile
Irshad Syed
NPI 1568499390
$2,163.47
in general payments reported to CMS, 2019-2025
28 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $203 · 2021: $165 · 2022: $215 · 2023: $334 · 2024: $150 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $419.17 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $309.13 | 2019-2025 | Mounjaro, Zepbound, Amyvid |
| Novo Nordisk INC | $196.91 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $137.34 | 2019 | |
| Pfizer INC. | $112.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $108.15 | 2019-2020 | |
| Biogen, INC. | $97.33 | 2021-2024 | Leqembi |
| Bayer Healthcare Pharmaceuticals INC. | $86.75 | 2022-2025 | |
| Amgen INC. | $81.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $67.34 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $60.97 | 2023-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $59.26 | 2023-2024 | Austedo Xr |
| Abbott Laboratories | $57.02 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $43.29 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $38.09 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $36.74 | 2019 | |
| Dexcom, INC. | $36.05 | 2022-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $32.84 | 2019 | |
| Gilead Sciences, INC. | $31.23 | 2025 | |
| Merck Sharp & Dohme LLC | $28.85 | 2019 | |
| Lundbeck LLC | $19.95 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $18.68 | 2019 | |
| Amarin Pharma, INC. | $18.05 | 2019 | |
| Exact Sciences Corporation | $17.42 | 2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $16.34 | 2020 | |
| Horizon Therapeutics Plc | $16.26 | 2023 | Krystexxa |
| Viiv Healthcare Company | $15.89 | 2024 | Apretude |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irshad Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.